fbpx Skip to main content

Public Policy Newsletter Article

2019 in Review

  • 2019-12-18T14:52:00.000+0000
  • California
  • Author: Jimmy Jackson

As everyone knows, a focus of public attention has been drug pricing, which has seen a great deal of activity in Washington DC. Biocom remained active in the drug pricing debate all year long, engaging with our members to find reasonable policies and educating congressional offices about the impact price controls and other proposals would have on California’s life science industry. We also published an op-ed expressing concerns with the Medicare Part D redesign provision in the Senate Finance Committee package and jointly commissioned a report to show the impact of H.R.3 on California’s research and development (R&D) pipeline. With its unique presence in the regulatory advocacy space, Biocom also submitted comment on a number of FDA regulatory and reimbursement issues. For a full summary of our federal efforts in 2019, click here.

At the state level, Biocom took a significant role in negotiations on several bills before the State Legislature this year. Biocom played a key role in securing the industry’s top priority amendment in the highest priority bill this year: AB 824, legislation which sets a presumption in law that any patent challenge settlement, whether executed in California or not, is anti-competitive and subject to significant penalties. Biocom, working as part of an opposition coalition with member companies, the Pharmaceutical Manufacturers and Research Association and other strategic partners, was the chief negotiator to successfully secure changes removing the onerous “clear and convincing” burden of proof for companies originally contained in the bill. For a recap of all of our efforts on the state level this year, click here.

A standout regional policy victory in 2019 was the Los Angeles County Board of Supervisors passage of a Bioscience Overlay Zone. Biocom worked with Supervisor Mark Ridley-Thomas and other county stakeholders to craft the measure, which will streamline the entitlement and permitting processes in the unincorporated county specifically for life science developments. In addition, we continue to bring regulators, policy makers and Biocom members together, offering our popular “Ask The Inspector” series in South San Francisco, the East Bay, and San Diego. We also hosted a variety of roundtables with elected officials throughout the state. Click here to read a full summary of our regional efforts.

More detail on the Public Policy Department’s efforts this year can be found in the Public Policy Newsletter.